The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $125.17 in the prior trading day, Transmedics Group Inc (NASDAQ: TMDX) closed at $126.24, up 0.85%. In other words, the price has increased by $0.85 from its previous closing price. On the day, 3.91 million shares were traded. TMDX stock price reached its highest trading level at $134.21 during the session, while it also had its lowest trading level at $126.13.
Ratios:
Our goal is to gain a better understanding of TMDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 9.37. In the meantime, Its Debt-to-Equity ratio is 2.72 whereas as Long-Term Debt/Eq ratio is at 2.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on September 24, 2024, initiated with a Outperform rating and assigned the stock a target price of $200.
On August 21, 2024, Needham started tracking the stock assigning a Buy rating and target price of $208.
On June 06, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $161.Cantor Fitzgerald initiated its Overweight rating on June 06, 2024, with a $161 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’24 when Hassanein Waleed H sold 8,625 shares for $132.71 per share. The transaction valued at 1,144,648 led to the insider holds 61,643 shares of the business.
Khayal Tamer I sold 2,958 shares of TMDX for $438,491 on Oct 01 ’24. The Chief Commercial Officer now owns 20,843 shares after completing the transaction at $148.24 per share. On Sep 16 ’24, another insider, Hassanein Waleed H, who serves as the President & CEO of the company, sold 8,625 shares for $153.42 each. As a result, the insider received 1,323,210 and left with 61,643 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4205597184 and an Enterprise Value of 4365027840. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3536.13, and their Forward P/E ratio for the next fiscal year is 66.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.74 while its Price-to-Book (P/B) ratio in mrq is 22.15. Its current Enterprise Value per Revenue stands at 12.167 whereas that against EBITDA is 101.968.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is -14.45%, while the 200-Day Moving Average is calculated to be 3.24%.
Shares Statistics:
The stock has traded on average 1.08M shares per day over the past 3-months and 1463680 shares per day over the last 10 days, according to various share statistics. A total of 32.67M shares are outstanding, with a floating share count of 32.23M. Insiders hold about 3.40% of the company’s shares, while institutions hold 103.16% stake in the company. Shares short for TMDX as of 1728950400 were 6439780 with a Short Ratio of 5.99, compared to 1726185600 on 5497500. Therefore, it implies a Short% of Shares Outstanding of 6439780 and a Short% of Float of 23.549999999999997.
Earnings Estimates
The current rating of Transmedics Group Inc (TMDX) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.28, with high estimates of $0.49 and low estimates of -$0.23.
Analysts are recommending an EPS of between $1.57 and $0.49 for the fiscal current year, implying an average EPS of $1.26. EPS for the following year is $1.91, with 10.0 analysts recommending between $3.45 and $0.59.
Revenue Estimates
9 analysts predict $115M in revenue for the current quarter. It ranges from a high estimate of $118.6M to a low estimate of $111M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $66.43MFor the next quarter, 9 analysts are estimating revenue of $119.37M. There is a high estimate of $124.7M for the next quarter, whereas the lowest estimate is $116M.
A total of 10 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $453.5M, while the lowest revenue estimate was $438M, resulting in an average revenue estimate of $444.36M. In the same quarter a year ago, actual revenue was $241.62MBased on 10 analysts’ estimates, the company’s revenue will be $582.74M in the next fiscal year. The high estimate is $635.05M and the low estimate is $525M.
